Published in
Taylor & Francis, Expert Opinion on Investigational Drugs, 2(29), p. 89-92, 2020
DOI: 10.1080/13543784.2020.1718106
Links
Tools
Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 